Trials / Withdrawn
WithdrawnNCT01302106
Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes
Phase II Study of Clofarabine in Combination With Low Dose Cytarabine for Untreated Patients With Poor Risk Myelodysplastic Syndromes
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Fondazione Italiana Sindromi Mielodisplastiche-ETS · Academic / Other
- Sex
- All
- Age
- 55 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is an interventional, multicenter, open label, phase II study designed to evaluate the safety and efficacy of Clofarabine in combination with low dose Cytarabine in untreated patients with poor risk of Myelodisplastic Syndromes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clofarabine plus low dose Ara-C | Clofarabine 10 mg/m2 by a 1-hr i.v infusion, once daily, from day 1 to 5. Ara-C 10 mg/m2, subcutaneously, twice a day (q12 hrs), from day 1 to 15. Clofarabine will be given 4 hours before the 2nd dose of Ara-C. |
Timeline
- First posted
- 2011-02-23
- Last updated
- 2013-10-01
Locations
21 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT01302106. Inclusion in this directory is not an endorsement.